News & Updates
Filter by Specialty:
Add-on favipiravir brightens outlook for hospitalized COVID-19 patients
When used in addition to standard of care, favipiravir leads to faster viral clearance and clinical improvement time among patients hospitalized with COVID-19, although it appears to contribute to an increased risk of hyperuricaemia, according to the results of a meta-analysis
Add-on favipiravir brightens outlook for hospitalized COVID-19 patients
06 May 2022Viruses causing gastroenteritis in children thrive in stools of asymptomatic carriers
The stools of asymptomatic patients carry the most common viruses that cause gastroenteritis in children and serve as a potential reservoir for acute gastroenteritis (AGE), a study has shown.
Viruses causing gastroenteritis in children thrive in stools of asymptomatic carriers
05 May 2022Nirmatrelvir-ritonavir cuts disease progression, viral load in unvaccinated COVID-19 outpatients
In the phase II/III EPIC-HR* trial, the novel oral antiviral nirmatrelvir-ritonavir reduced the risk of progression of COVID-19 to severe disease, as well as viral load, in symptomatic, high-risk, unvaccinated nonhospitalized adults confirmed to have SARS-CoV-2 infection.
Nirmatrelvir-ritonavir cuts disease progression, viral load in unvaccinated COVID-19 outpatients
04 May 2022One in 10 patients fully recover from consciousness disorders after severe COVID-19
Among patients who suffer from disorders of consciousness (DoC) after severe COVID-19, around 10 percent can achieve functional independence after 1 year, reports a study presented at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).
One in 10 patients fully recover from consciousness disorders after severe COVID-19
28 Apr 2022Annual flu jab in HF patients may lower hospitalization, pneumonia risk
An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.